Antengene Corp Ltd

On the eve of the BIO International Convention 2026, the BIOSeedin Summer Innovation Partnering Summit in San Diego showcased China's differentiated innovative assets, drawing over 350 registrants and more than 200 on-site attendees from over 30 countries and regions. The summit, hosted by bioSeedin with strategic partners Thermo Fisher Scientific and ACROBiosystems, featured two sessions: one on early-stage strategy and innovation, where panelists emphasized that multinational corporations now view China as a core innovation fountain, and another on late-stage global ecosystems, highlighting that China and AI are permanent structural forces in the industry. Roadshow presentations were delivered by companies including Antengene, GeneScience Pharmaceutical, Salsola Therapeutics, HighTide Therapeutics, and others. The bioSeedin 1on1 Partnering System facilitated nearly 200 face-to-face meetings, reflecting strong interest in cross-border licensing and collaboration.

Antengene Corporation has signed an exclusive license agreement with K2 Therapeutics for ATG-106 and an option agreement for an undisclosed preclinical bispecific T-cell engager. Under the ATG-106 deal, Antengene will receive upfront and near-term consideration of approximately $20 million in cash and a minority equity stake in a new asset company, plus potential milestone payments of up to $960.5 million and tiered royalties on future net sales. Under the option agreement for the undisclosed TCE, upon exercise Antengene would receive about $20 million in option exercise fee, near-term payment, upfront payment, and a minority equity stake, along with up to $960.5 million in milestones and tiered royalties. Both programs use Antengene's proprietary AnTenGager platform, and K2 Therapeutics' rights cover all territories outside Greater China.